Clinical trials: Ivonescimab
SCLC, Recurrent
Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC
This is a multicenter, open-label, single-arm phase 2 study evaluating the efficacy and safety of ivonescimab combined with paclitaxel polymeric micelles in adults with recurrent or refractory small cell lung cancer after failure…
- Trial name
- NCT07819591
- Testing
- Paclitaxel Polymeric Micelles, Ivonescimab
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Shaodong Hong
Neuroendocrine Cancer
AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer
This study is a single prospective, parallel, double-cohort, multicenter phase II clinical trial, aiming to evaluate the efficacy and safety of ivonescimab (AK112) combined with IP chemotherapy ± TACE in the first-line treatment…
- Trial name
- NCT07712094
- Testing
- AK112, Irinotecan, Cisplatin
- Where
- 8 sites in China
- Volunteers
- 56 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Locally Advanced Rectal Cancer
Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer
This study is a single-arm, prospective, phase II clinical study to evaluate the efficacy and safety of preoperative short-course radiotherapy combined with ivonescimab and chemotherapy + total mesorectal excision(TME) surgery in…
- Trial name
- NCT06760520
- Testing
- Ivonescimab (SMT112 or AK112) Injection
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
The goal of this clinical trial is to evaluate the addition of ivonescimab to standard chemotherapy in patients with advanced or metastatic gastric and gastroesophageal adenocarcinoma.
- Conditions
- Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Advanced Gastric Adenocarcinoma
- Trial name
- GRACIE (NCT06846346)
- Testing
- Ivonescimab, FOLFOX regimen, Irinotecan
- Where
- 4 sites in France
- Volunteers
- 88 people
- Sponsor
- UNICANCER
LOCALLY ADVANCED CERVICAL CANCERS
Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer
This is a single-arm, phase II clinical trial evaluating the efficacy and safety of neoadjuvant Ivonescimab combined with paclitaxel and cisplatin (TP regimen), followed by concurrent chemoradiotherapy, in patients with…
- Trial name
- NCT07244965
- Testing
- Ivonescimab Combined With Chemotherapy, CONCURRENT CHEMORADIATION (CISPLATIN)
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
This phase II/III trial studies how well the addition of ivonescimab to standard chemotherapy (gemcitabine and cisplatin) works when compared to usual chemotherapy and immunotherapy (durvalumab or pembrolizumab) in treating…
- Conditions
- Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Adenocarcinoma
- Trial name
- NCT07765433
- Testing
- Biospecimen Collection, Cisplatin, Computed Tomography
- Volunteers
- 336 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Squamous Cell Lung Cancer
Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.
This is a prospective, single-arm, multi-center, phase Ⅱ trial to evaluate the efficacy and safety of Polymeric Micelles paclitaxel(pm-Pac), platinum (cisplatin/carboplatin) in combination with Ivonescimab as first-line treatment…
- Trial name
- NCT07009925
- Testing
- Ivonescimab 20mg/kg intravenous every 3 weeks
- Volunteers
- 38 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Nasopharyngeal Carcinoma (NPC)
Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
This trial aims to study the role of Ivonescimab combined with chemoradiotherapy in high-Risk locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT07064902
- Testing
- Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- Where
- 3 sites in China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Multiple Advanced Tumors After PD-1 Therapy Failure
Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure
The goal of this clinical trial is to learn if the combination of radiofrequency ablation (RFA) and Ivonescimab (PD-1/VEGF Bispecific Antibody) works to could reverse PD-1/PD-L1 resistance in patients with advanced tumors.
- Trial name
- NCT07095803
- Testing
- Ivonescimab (20mg/kg Q3W), radiofrequency ablation
- Volunteers
- 60 people
- Sponsor
- Sheng Zhang
Non-Small Cell Lung Cancer
A Study of Ivonescimab in People With Non-Small Cell Lung Cancer
The researchers are doing this study to find out whether ivonescimab after receiving standard stereotactic body radiotherapy (SBRT) is an effective treatment in people with Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT07594522
- Testing
- Photon or Proton standard stereotactic body radiotherapy (SBRT), Ivonescimab
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma
Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.
This study is a single-center, open-label Phase II clinical trial, aiming to enroll approximately 30 unresectable BCLC stage B or C hepatocellular carcinoma (HCC) patients from China.
- Trial name
- NCT06375486
- Testing
- Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
NSCLC (Advanced Non-small Cell Lung Cancer)
A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment
This is a prospective, single-center, Phase II clinical study designed to explore the efficacy and safety of ivonescimab plus third-generation EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer who…
- Trial name
- NCT07669051
- Testing
- ivonescimab plus EGFR-TKI.
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shandong Cancer Hospital and Institute
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
In the past few decades, surgery, radiotherapy, chemotherapy and other treatments were continuously improved, however, the mortality of esophageal squamous cell carcinoma patients was not significantly decreased.
- Trial name
- NCT07244978
- Testing
- Ivonescimab（AK112), Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy, Esophagectomy, Sample
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Advanced Non-small Cell Lung Cancer (NSCLC)
AMT-116 in Combination With AK112 in Patients With Lung Cancer
The purpose of this study is to evaluate the safety and efficacy of AMT-116 in combination with Ivonescimab (AK112) in patients with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT07590531
- Testing
- AMT-116, AK112
- Where
- 2 sites in China
- Volunteers
- 118 people
- Sponsor
- Multitude Therapeutics Inc.
Endometrial Cancer, Cervical Cancer
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
The researchers are doing this study to find out if ivonescimab is an effective treatment for people with endometrial cancer (EC) and/or cervical cancer (CC).
- Trial name
- NCT06925724
- Testing
- Ivonescimab
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rectal Adenocarcinoma
A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer
The purpose of this study is to evaluate the efficacy and safety of short-course radiotherapy followed by ivonescimab and chemotherapy in participants with pMMR/MSS locally advanced rectal cancer.
- Trial name
- NCT06919510
- Testing
- lvonescimab, CAPOX (oxaliplatin/capecitabine), radiotherapy
- Volunteers
- 90 people
- Sponsor
- Sun Yat-sen University
TNBC, Triple Negative Breast Cancer
Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer
This study is a multicenter, single-arm, investigator-initiated Phase II clinical trial. Eligible patients with treatment-naive early or locally advanced triple-negative breast cancer (TNBC), clinically staged as Stage II-III…
- Trial name
- NCT06977542
- Testing
- Ivonescimab
- Volunteers
- 53 people
- Sponsor
- Fudan University
Small-cell Lung Cancer
A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC
This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of ivonescimab combined with irinotecan liposome for relapsed small cell lung cancer, who progressed on PD-(L)1 -based first-line…
- Trial name
- NCT06478043
- Testing
- ivonescimab, irinotecan liposome
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Non-Small Cell Lung Cancer
A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
This is a prospective, single-arm, multi-center, phase II clinical trial to evaluate the efficacy and safety of Chidamide in combination with Ivonescimab in the treatment of advanced non-small cell lung cancer with secondary…
- Trial name
- NSCLC， YAP (NCT07412262)
- Testing
- Chidamide in combination with Ivonescimab
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- Guangdong Association of Clinical Trials
Localized Clear Cell Renal Cell Carcinoma, Resectable Clear Cell Renal Cell Carcinoma
Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer
This phase II trial studies how well ivonescimab works prior to surgery in treating patients with high-risk clear cell kidney (renal cell) cancer that has not spread to other parts of the body (localized).
- Conditions
- Localized Clear Cell Renal Cell Carcinoma, Resectable Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8
- Trial name
- NCT07226544
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center